| Obinutuzumab for relapsed or refractory indolent non-Hodgkin’s lymphomas L Gabellier, G Cartron Therapeutic advances in hematology 7 (2), 85-93, 2016 | 34 | 2016 |
| Discovery and mechanism of action of small molecule inhibitors of ceramidases RD Healey, EM Saied, X Cong, G Karsai, L Gabellier, J Saint‐Paul, ... Angewandte Chemie International Edition 61 (2), e202109967, 2022 | 20 | 2022 |
| The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemias R Paolillo, M Boulanger, P Gâtel, L Gabellier, M De Toledo, D Tempé, ... Haematologica 107 (11), 2562, 2022 | 18 | 2022 |
| Cytomegalovirus Infection With Retinitis After Brentuximab Vedotin Treatment for CD30+ Lymphoma JJ Tudesq, L Vincent, J Lebrun, Y Hicheri, L Gabellier, T Busetto, C Merle, ... Open Forum Infectious Diseases 4 (2), ofx091, 2017 | 18 | 2017 |
| Second-and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation—a … K Hirschbühl, M Labopin, M Houhou, L Gabellier, H Labussière-Wallet, ... Bone Marrow Transplantation 56 (5), 1190-1199, 2021 | 17 | 2021 |
| DNA repair expression profiling to identify high-risk cytogenetically normal acute myeloid leukemia and define New Therapeutic Targets L Gabellier, C Bret, G Bossis, G Cartron, J Moreaux Cancers 12 (10), 2874, 2020 | 4 | 2020 |
| SUMOylation inhibitor TAK-981 (subasumstat) synergizes with 5-azacytidine in preclinical models of acute myeloid leukemia L Gabellier, M De Toledo, M Chakraborty, D Akl, R Hallal, M Aqrouq, ... Haematologica 109 (1), 98, 2024 | 3 | 2024 |
| DeSUMOylation of chromatin-bound proteins limits the rapid transcriptional reprogramming induced by daunorubicin in acute myeloid leukemias M Boulanger, M Aqrouq, D Tempé, C Kifagi, M Ristic, D Akl, R Hallal, ... Nucleic Acids Research 51 (16), 8413-8433, 2023 | 3 | 2023 |
| Formative assessment of diagnostic testing in family medicine with comprehensive MCQ followed by certainty-based mark C Herbaux, A Dupré, W Rénier, L Gabellier, E Chazard, P Lambert, ... Healthcare 10 (8), 1558, 2022 | 3 | 2022 |
| Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a … S Garciaz, S Bertoli, DA Sallman, J Decroocq, PY Dumas, A Belhabri, ... Blood 142, 161, 2023 | 2 | 2023 |
| Preventive plasmapheresis for rituximab related flare in cryoglobulinemic vasculitis L Fornero, T Kanouni, JJ Tudesq, C Pochard, P Verot, W Renier, ... Journal of Translational Autoimmunity 6, 100194, 2023 | 1 | 2023 |
| Clinical presentation, outcome, and prognostic markers in patients with intravascular large B‐cell lymphoma, a lymphoma study association (LYSA) retrospective study A Bonnet, C Bossard, L Gabellier, J Rohmer, O Laghmari, M Parrens, ... Cancer Medicine 11 (19), 3602-3611, 2022 | 1 | 2022 |
| Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human … J Loke, M Labopin, C Craddock, G Socié, T Gedde‐Dahl, D Blaise, ... Cancer, 2024 | | 2024 |
| Posters 12 Néoplasies myéloprolifératives et leucémie myéloïde chronique S Bonnet, S Carillo, B Legrand, B Burroni, T Lavabre-Bertrand, R Guilhem, ... Hématologie 30 (2), 121, 2024 | | 2024 |
| Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin (CALR) in exon 3 S Bonnet, S Carillo, B Legrand, B Burroni, T Lavabre‐Bertrand, ... European Journal of Haematology 112 (3), 475-478, 2024 | | 2024 |
| Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study L Gabellier, P Peterlin, S Thepot, Y Hicheri, F Paul, MP Gallego-Hernanz, ... Annals of Hematology, 1-11, 2024 | | 2024 |
| The SUMOylation inhibitor TAK-981 (Subasumstat) triggers IFN-I-dependent activation of Natural Killer cells against Acute Myeloid Leukemias. R Hallal, M De Toledo, D Tempe, S Zemiti, L Coenon, D Gitenay, ... bioRxiv, 2024.02. 19.580882, 2024 | | 2024 |
| Efficacy and Tolerance of Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Graall Study from the Descar-T Registry F Rabian, D Beauvais, T Marchand, S Furst, A Huynh, E Brissot, S Maury, ... Blood 142, 3498, 2023 | | 2023 |
| Early Progressions of Undetermined Significance (EPUS) in the Month Following CAR-T Cells for B-Cell NHL Is Mainly Related to Pseudoprogression B Tisserand, C Bret, Y Al Tabaa, S Lamure, X Ayrignac, L Platon, ... Blood 142, 3124, 2023 | | 2023 |
| Clinico‐biological features, treatment and prognosis of primary myeloid sarcoma: A French retrospective multi‐centric observational study M Belhadj, B Burroni, O Kosmider, L Willems, M Temple, S Bertoli, ... British Journal of Haematology 202 (6), e50-e53, 2023 | | 2023 |
